CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable predictive tools are available for identifying potentially responsive or insensitive tumors. We had shown that the activating T172 phosphorylation of CDK4 is the central rate‐limiting event that initiates the cell cycle decision and signals the presence of active CDK4. Here, we report that the profile of post‐translational modification including T172 phosphorylation of CDK4 differs among breast tumors and associates with their subtypes and risk. A gene expression signature faithfully predicted CDK4 modification profiles in tumors and cell lines. Moreover, in breast cancer cell lines, the CDK4 T172 phosphorylation best correlated with sensitivity to PD0332991. This gene expression signature identifies tumors that are unlikely to respond to CDK4/6 inhibitors and could help to select a subset of patients with HER2‐positive and basal‐like tumors for clinical studies on this class of drugs.

[1]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[2]  G. Peters,et al.  Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.

[3]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[4]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[5]  B. Amati,et al.  Cyclin E and c‐Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins , 1997, The EMBO journal.

[6]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[7]  Anne-Marie Duchemin,et al.  Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.

[8]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[9]  Rafael A Irizarry,et al.  Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.

[10]  R. Sutherland,et al.  Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells , 2014, BMC Cancer.

[11]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[12]  Benjamin Haibe-Kains,et al.  DNA methylation profiling reveals a predominant immune component in breast cancers , 2011, EMBO molecular medicine.

[13]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[14]  F. Setién,et al.  Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer , 2016, Proceedings of the National Academy of Sciences.

[15]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[16]  Tuan S. Nguyen,et al.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.

[17]  M. Dickson.  Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy , 2014 .

[18]  Amanda C. Schierz,et al.  canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic Acids Res..

[19]  C. Fan,et al.  PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.

[20]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[21]  J. Dumont,et al.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. , 2010, Molecular endocrinology.

[22]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[23]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[24]  J. Dumont,et al.  Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. , 2008, Molecular biology of the cell.

[25]  E. Knudsen,et al.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.

[26]  C. Sherr,et al.  D-type cyclins. , 1995, Trends in biochemical sciences.

[27]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[28]  Tae J. Lee,et al.  A bistable Rb–E2F switch underlies the restriction point , 2008, Nature Cell Biology.

[29]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[30]  J. Bartek,et al.  The retinoblastoma protein pathway and the restriction point. , 1996, Current opinion in cell biology.

[31]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Massagué,et al.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1 ) of cyclin-dependent kinase 4 activation , 1994, Cell.

[33]  Charles M. Perou,et al.  Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.

[34]  A. Dicker,et al.  The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. , 2011, Cell cycle.

[35]  K. Coulonval,et al.  Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase , 2010, Cell cycle.

[36]  J. Infante,et al.  Targeting CDK4/6 in patients with cancer. , 2016, Cancer treatment reviews.

[37]  Karl A. Merrick,et al.  A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. , 2013, Molecular cell.

[38]  A. Look,et al.  The requirement for cyclin D function in tumor maintenance. , 2012, Cancer cell.

[39]  D B Evans,et al.  Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole , 2010, The Pharmacogenomics Journal.

[40]  S. Reed,et al.  Cyclin E-induced S phase without activation of the pRb/E2F pathway. , 1997, Genes & development.

[41]  H. Rui,et al.  RB-pathway disruption in breast cancer , 2010, Cell cycle.

[42]  S. Paternot,et al.  Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation , 2009, Molecular and Cellular Biology.

[43]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  T. Slater,et al.  STUDIES ON SUCCINATE-TETRAZOLIUM REDUCTASE SYSTEMS. III. POINTS OF COUPLING OF FOUR DIFFERENT TETRAZOLIUM SALTS. , 1963, Biochimica et biophysica acta.

[46]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[47]  G. Peters,et al.  Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all , 2006, Nature Reviews Molecular Cell Biology.

[48]  F. Kaye,et al.  Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. , 1999, American journal of human genetics.

[49]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[50]  A. Giobbie-Hurder,et al.  The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. , 2016, JAMA oncology.

[51]  J. Dumont,et al.  A mechanism generating heterogeneity in thyroid epithelial cells: suppression of the thyrotropin/cAMP-dependent mitogenic pathway after cell division induced by cAMP-independent factors , 1992, The Journal of cell biology.

[52]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[53]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[55]  Charles M Perou,et al.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas , 2008, Breast Cancer Research.

[56]  Y. Nakamura,et al.  Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild‐type TP53 expression system , 1998, Genes, chromosomes & cancer.

[57]  L. Hengst,et al.  CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point , 2013, PLoS genetics.

[58]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[59]  D. Heitjan,et al.  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.

[60]  Y. De Launoit,et al.  Regulated Activating Thr172 Phosphorylation of Cyclin-Dependent Kinase 4(CDK4): Its Relationship with Cyclins and CDK “Inhibitors” , 2006, Molecular and Cellular Biology.

[61]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[62]  S. Lowe,et al.  The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. , 2007, The Journal of clinical investigation.

[63]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[64]  J. Dumont,et al.  Cyclic AMP-dependent Phosphorylation of Cyclin D3-bound CDK4 Determines the Passage through the Cell Cycle Restriction Point in Thyroid Epithelial Cells* , 2003, Journal of Biological Chemistry.

[65]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[66]  R. Blamey,et al.  INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  Frederick S. Vizeacoumar,et al.  RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs , 2013, PloS one.

[68]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[69]  Robert A. Weinberg,et al.  Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.

[70]  S. Paternot,et al.  Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. , 2009, Cancer research.

[71]  G. Mills,et al.  ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.

[72]  F. Sadeghi,et al.  Abstract 4: Inhibitory effects of aprotinin on survival and local invasion of human breast cancer cell lines , 2017 .

[73]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[74]  C. Sherr,et al.  Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase , 1994, Molecular and cellular biology.

[75]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[76]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[77]  Jean Y. J. Wang,et al.  Targeting the RB-pathway in Cancer Therapy , 2010, Clinical Cancer Research.

[78]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[79]  K. Coulonval,et al.  Regulation of CDK4 , 2006, Cell Division.